Propofol inhibits migration and induces apoptosis of pancreatic cancer PANC-1 cells through miR-34a-mediated E-cadherin and LOC285194 signals
Authors: Hongwei Wang
Renyi Chen
Hongmei Jiao
Ziru Jiang
Journal: Bioengineered (2020)
Discipline: BIOLOGY & BIOCHEMISTRY
Keywords: E-cadherin; Pancreatic cancer; apoptosis; long non-coding RNA LOC285194; microRNA-34a
Affiliations: Department of Anesthesia, Linyi Cancer Hospital, Linyi, Shandong, China, External Abdominal Section, Linyi Cancer Hospital, Linyi, Shandong, China

Abstract:  Propofol has exhibited potent antitumor activity in pancreatic cancer cells in vitro and in vivo. The study aimed to investigate the anti-tumor mechanisms of propofol on pancreatic cancer PANC-1 cells in vitro. PANC-1 cells were exposure to concentration 20 μg/ml of propofol for 72 h. Long non-coding RNA LOC285194 siRNA LOC285194 siRNA, E-cadherin siRNA and microRNA-34a (miR-34a) inhibitor were used to investigate the effect of propofol on PANC-1 cells. miR-34a and LOC285194 were analyzed by quantitative real-time PCR (qRT-PCR). Pro-apoptotic protein bax, cleaved-caspase-3 and anti-apoptotic protein bcl-2 were analyzed by Western blot. Cell viability and cell apoptosis were detected by MTT and TUNEL staining, respectively. Cell migration was detected by wound-healing assay. The results showed that propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression, resulting in PANC-1 cell apoptosis and growth inhibition. In addition, propofol upregulated miR-34a expression, which, in turn, upregulated E-cadherin expression, resulting in cell migration inhibition. Our research confirmed that propofol-induced cell apoptosis and inhibited cell migration in PANC-1 cells in vitro via promoting miR-34a-dependent LOC285194 and E-cadherin upregulation, respectively. 

Retracted: No

PubPeer comments:
 Um. *** ![file] *** ![file] , 
 I should also note that the corresponding authoru2018s email address bears no resemblance to their name. This is sometimes found with paper mill papers, although a photo of a plateau pika is unexpected even so. , 
 The corresponding authoru2018s email should be mzchenrenyi@126.com; The first author should be WHW13792969744@163.com. The submitting author is the corresponding author by default, so the mailbox cannot be changed, and the corresponding author s mailbox is the first author s. During the correction, the picture was found to be wrong, and the magazine was requested to change it, but the article was invalidated without the change. , 
 #3 Thank you for responding, however Iu2019m not sure I understand. Are you saying the paper mill submitted the paper using the wrong corresponding authoru2019s email and now the journal will not permit you to correct the paper? , 
 No. The submitting author is the corresponding author by default in the submitting system. , 
 #5 So long as you are here, please also take a look at your co-author Hongwei Wang s case: https: pubpeer.com publications EB25B3BDAFC243C65B20A0BB804595#5 , 
 #2 In addition,we did not pay the publishing fee uff0cbecause the Fig3 was not corrected. , 
 #7 I am still confused about what all has gone wrong. Could the authors please provide their institutional email addresses or the person responsible for research integrity at your hospital? I may be able to help contact the journal to request a correction (after the authors provide the correct figure), but want to be sure the real authors agree with this approach. Otherwise, I can request that the journal retract the article. , 
 Let s withdraw this article. Thanks. The Journal must know about this problem . We can no longer use this article. ,